Effect of ultralow doses of antibodies to erythropoietin on antenatal and postnatal development of the offspring.

We studied the effects of ultralow doses of antibodies to erythropoietin on antenatal and postnatal development of rat offspring. Daily administration of the preparation on days 1-6, 6-16, and 16-19 of pregnancy did not increase embryonic mortality and was not associated with congenital malformations, fetal growth retardation, high incidence of pathological changes in fetal organs, and delayed ossification (compared to control and intact animals). For evaluation of their embryotoxic effect manifested in the postnatal period ultralow doses of antibodies to erythropoietin were administered throughout pregnancy. The offspring of treated and intact rats did not differ in physical development, appearance of sensory and locomotor reflexes, locomotor, exploratory, and emotional behavior, and learning and adaptive capacities.

Effects of ultralow doses of antibodies to prostate-specific antigen on morphological and functional state of rat prostate.

Morphological and morphometric assays showed that administration of antibodies to the prostate-specific antigen in ultralow doses for 1.5 months delayed the development of atrophic and sclerotic processes in rats with chronic aseptic prostatitis. The concentration of zinc ions playing an important role in binding of androgens increased in the prostate of rats receiving the preparation. Studies of copulatory behavior showed that male rats with chronic prostatitis receiving antibodies to the prostate-specific antigen displayed increased sexual activity compared to control and intact animals.

[Preclinical toxicologic study of a Baikal aconite tincture (bayacon)]. / Doklinicheskoe toksikologicheskoe izuchenie nastoiki akonita baikal'skogo (Baiakona).

The safety of bayacon, a new drug based on Baikal aconite intended for the treatment of inflammation-proliferative dermatitis (psoriasis), was studied on a preclinical level. With respect to a single introduction in rats and mice, the drug is classified as a low-toxicity substance. However, a 3-month oral administration of bayacon (0.25, 0.5, and 2.5 mg/kg) in rats showed a number of dose-dependent functional and morphological changes. A dose of 2.5 mg/kg induced weak hyporegenerative anemia, neutrophile leukocytosis, and dystrophic changes in the stomach mucosa, heart, liver, and kidneys. All these symptoms disappeared within two weeks after abolition of the drug. Oral administration of bayacon (0.1 and 0.5 mg/kg) in rabbits produced no pathological morphofunctional changes in the organs and tissues studied. In rats, bayacon 2.5, 0.5, and 0.25 mg/kg doses of bayacon led to dose-dependent changes in some characteristics of the reproduction system. The drug did not influence the expression of allergic reactions and showed no immunotoxicity and mutagenicity manifestations.

Early and delayed effects of carboplatin on the blood system.

Carboplatin injected intravenously in a maximum permissible dose to Wistar rats inhibited erythro- and granulocytopoiesis in the bone marrow, caused hyporegenerative anemia, leukopenia, and thrombocytopenia in the peripheral blood, led to hypoplasia of the thymus and spleen, and produced moderate apoptosis-inducing effects. These effects were observed within the first month after treatment. In mice carboplatin induced chromatid aberrations in the bone marrow and increased the count of erythrocytes with micronuclei. Moderate hypoplasia of erythro- and granulocytopoiesis and accelerated involution of the thymus were observed 3 and 6 months after cytostatic treatment. Our results indicate that carboplatin possesses higher myelotoxic activity compared to cisplatin.